Comparative Analysis of Thermal Ablation and Hepatectomy for Solitary Colorectal Liver Metastases up to 5 cm: Insights from a Multicenter Trial Emulation on Safety, Effectiveness, and Economic Viability - Scorecard - MDSpire

Comparative Analysis of Thermal Ablation and Hepatectomy for Solitary Colorectal Liver Metastases up to 5 cm: Insights from a Multicenter Trial Emulation on Safety, Effectiveness, and Economic Viability

  • By

  • Jianming Li

  • Lu Li

  • Guangjian Liu

  • Huarong Li

  • Xiaoyan Xie

  • Haibo Shao

  • Lingwei Li

  • De-zhi Zhang

  • Kai Li

  • Zhishuai Li

  • Guangbin He

  • Erjiao Xu

  • Huage Zhong

  • Hong Yang

  • Man Lu

  • Kexin Lou

  • Xiang Xie

  • Qian Li

  • Yu Song

  • Yongyan Gao

  • Xiaohui Ji

  • Bin Ren

  • Jie Yu

  • Ping Liang

  • March 5, 2026

  • 0 min

Share

Clinical Scorecard: Comparative Analysis of Thermal Ablation and Hepatectomy for Solitary Colorectal Liver Metastases up to 5 cm: Insights from a Multicenter Trial Emulation on Safety, Effectiveness, and Economic Viability

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with solitary colorectal liver metastases ≤ 5 cm
Care Setting

Key Highlights

  • Clarify that TA is non-inferior to HT specifically for tumors < 3 cm, and note the lack of data for 3-5 cm.

Guideline-Based Recommendations

Diagnosis

    Management

    • Consideration of HT or TA based on tumor and patient factors, referencing ESMO and NCCN guidelines.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Individualized treatment strategies based on tumor characteristics, patient preferences, and clinical guidelines.

        Clinical Best Practices

        • Document patient preferences and treatment discussions, emphasizing patient education.

        References

        Original Source(s)

        Comparative Analysis of Thermal Ablation and Hepatectomy for Solitary Colorectal Liver Metastases up to 5 cm: Insights from a Multicenter Trial Emulation on Safety, Effectiveness, and Economic Viability

        • by Jianming Li, Lu Li, Guangjian Liu, Huarong Li, Xiaoyan Xie, Haibo Shao, Lingwei Li, De-zhi Zhang, Kai Li, Zhishuai Li, Guangbin He, Erjiao Xu, Huage Zhong, Hong Yang, Man Lu, Kexin Lou, Xiang Xie, Qian Li, Yu Song, Yongyan Gao, Xiaohui Ji, Bin Ren, Jie Yu, Ping Liang

        • March 5, 2026

        Related Content

        Reply to: Clarifying multimodal inputs and attribution in colorectal cancer survival prediction

        The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

        Nitidine chloride suppresses polo-like kinase 1 via MYCN-associated transcriptional regulation in colorectal cancer: a multi-omics and spatial transcriptomics study